OPA1 and chronic kidney disease: Dramatically, restoration of YME1L1 expression significantly alleviates cisplatin‐induced AKI and subsequent chronic kidney disease (CKD) through attenuating mitochondrial dysfunction via maintaining optic atrophy 1 (OPA1)‐mediated mitochondrial energy metabolism homeostasis.